Search results for "COLON"

showing 10 items of 2038 documents

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

2021

[Background]: The fungal community of the gastrointestinal tract has recently become of interest, and knowledge of its relationship with the development of obesity is scarce. The present study aimed to evaluate the cultivable fungal fraction from the microbiota and to analyze its relationship with obesity.

AdultMale0301 basic medicineColony Count MicrobialMedicine (miscellaneous)030209 endocrinology & metabolismOverweightCandida parapsilosis03 medical and health sciences0302 clinical medicineWeight lossYeastsCandida kruseimedicineHumansObesityFood scienceCandida albicansCandida030109 nutrition & dieteticsNutrition and DieteticsbiologyCandida glabratabusiness.industryFungiDiscriminant AnalysisRhodotorulaOverweightbiology.organism_classificationmedicine.diseaseObesityGastrointestinal TractSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationFemalemedicine.symptombusinessWeight gainMycobiome
researchProduct

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in pati…

1993

After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte - colony stimulating factor (G- CSF) 5 μg/Kg/day in order to prevent severe neutropenia and its related morbidity. The incidence of neutropenia (absolute neutrophil count <1, 000/mm3) was significantly reduced in patients receiving G-CSF than in controls (18% versus 42%; P <0.05). The duration of neutropenia was also shortened by the administration of G-CSF (4.8 versus 8.2 days; P <0.05). Therapy with G-CSF has also a positive impact on the dose-intensity of employed regimens. Patients treated with G-CSF showed…

AdultMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeutropeniaTime FactorsFeverInjections Subcutaneousmedicine.medical_treatment030106 microbiologyAntineoplastic AgentsNeutropeniaGranulocytePlaceboGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Prospective StudiesNeoplasm MetastasisAgedPharmacologyChemotherapybusiness.industryIncidenceIncidence (epidemiology)CarcinomaMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryInfectious DiseasesGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncology030220 oncology & carcinogenesisAbsolute neutrophil countFemalebusinessmedicine.drug
researchProduct

Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extr…

2021

Colorectal cancer (CRC) with microsatellite instability (MSI) accounts for 15-18 % of all CRCs and represents the category with the best prognosis. This study aimed at determining any possible clinical/pathological features associated with a higher risk of nodal metastasization in MSI-CRC, and at defining any possible prognostic moderators in this setting. All surgically resected CRCs of the last 20 years (mono-institutional series) with a PCR-based diagnosis of MSI, with and without nodal metastasis, have been retrieved for histological review, which was performed following WHO guidelines. Furthermore, the most important prognostic moderators have been investigated with a survival analysis…

AdultMale0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPrognostic variableColonColorectal cancerDisease-Free SurvivalMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineInternal medicinedMMRmedicinerectumHumansStage (cooking)neoplasmsMSISurvival analysisAgedColon; ENE; Extracapsular; MSI; Metastasis; dMMR; rectumExtranodal ExtensionExtracapsularSignet ring cellbusiness.industryColon; dMMR; ENE; Extracapsular; Metastasis; MSI; rectumMicrosatellite instabilityCell BiologyMiddle AgedPrognosismedicine.diseaseProgression-Free Survivaldigestive system diseases030104 developmental biology030220 oncology & carcinogenesisENEFemaleMicrosatellite InstabilityColorectal NeoplasmsNODALbusinessCarcinoma Signet Ring CellPathology - Research and Practice
researchProduct

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 ove…

2018

At the histological level, tumor budding in colon cancer is the result of cells undergoing at least partial epithelial-to-mesenchymal transition. The microRNA 200 family is an important epigenetic driver of this process, mainly by downregulating zinc-finger E-box binding homeobox (ZEB) and transforming growth factor beta (TGF-β) expression. We retrospectively explored the expression of the miR200 family, and ZEB1 and ZEB2, and their relationship with immune resistance mediated through PD-L1 overexpression. For this purpose, we analyzed a series of 125 colon cancer cases and took samples from two different tumor sites: the area of tumor budding at the invasive front and from the tumor center…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyEpithelial-Mesenchymal TransitionColorectal cancerPD-L1 OverexpressionBiologyB7-H1 AntigenPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineTumor buddingmicroRNAmedicineHumansAgedRetrospective StudiesAged 80 and overBuddingMesenchymal stem cellTransforming growth factor betaMiddle Agedmedicine.disease3. Good healthMicroRNAs030104 developmental biology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchbiology.proteinBiomarker (medicine)FemaleModern Pathology
researchProduct

Carriage of Enterobacteria Producing Extended-Spectrum β-Lactamases and Composition of the Gut Microbiota in an Amerindian Community

2015

ABSTRACT Epidemiological and individual risk factors for colonization by enterobacteria producing extended-spectrum beta-lactamases (E-ESBL) have been studied extensively, but whether such colonization is associated with significant changes in the composition of the rest of the microbiota is still unknown. To address this issue, we assessed in an isolated Amerindian Guianese community whether intestinal carriage of E-ESBL was associated with specificities in gut microbiota using metagenomic and metatranscriptomic approaches. While the richness of taxa of the active microbiota of carriers was similar to that of noncarriers, the taxa were less homogeneous. In addition, species of four genera,…

AdultMale0301 basic medicinefood.ingredient030106 microbiologyGene ExpressionGut floradigestive systembeta-LactamasesCoprococcusMicrobiologyFeces03 medical and health sciencesfluids and secretionsfoodEnterobacteriaceaeMechanisms of ResistancePhylogeneticsRNA Ribosomal 16SHumansPharmacology (medical)ColonizationPhylogenyAgedPharmacologybiologyEnterobacteriaceae InfectionsSequence Analysis DNAMiddle Agedbiology.organism_classificationParabacteroidesDesulfovibrioEnterobacteriaceaeFrench GuianaGastrointestinal Microbiomestomatognathic diseasesInfectious DiseasesGenes BacterialMetagenomicsCarrier StateIndians North AmericanbacteriaMetagenomeDesulfovibrioFemaleTranscriptomeAntimicrobial Agents and Chemotherapy
researchProduct

A Randomized, Blinded, Prospective Trial to Compare the Safety and Efficacy of Three Bowel-Cleansing Solutions for Colonoscopy (HSG-01*)

2003

BACKGROUND AND STUDY AIMS There are conflicting data regarding the optimal bowel preparation for colonoscopy. This study was carried out to compare the efficacy, safety, and tolerability of three widely used bowel lavage solutions: the standard polyethylene glycol-electrolyte solution based on the GoLytely formulation (PEG-EL1; Klean-Prep); a sulphate-free PEG-EL solution based on the NuLytely formulation (PEG-EL2, Endofalk); and a sodium phosphate preparation (NaP, Fleet Phospho-Soda). PATIENT AND METHODS A total of 185 consecutive patients scheduled for elective colonoscopy were prospectively randomly assigned to undergo pre-colonoscopic bowel cleansing with either 4 l of PEG-EL1 (n=64), …

AdultMaleAbdominal painmedicine.medical_specialtyRandomizationAdolescentNauseaRectumColonoscopyPhosphatesPolyethylene GlycolsElectrolytesPatient satisfactionmedicineHumansAscending colonProspective StudiesAgedmedicine.diagnostic_testCatharticsbusiness.industryGastroenterologyColonoscopyMiddle AgedSurgerySolutionsmedicine.anatomical_structureTolerabilityFemalemedicine.symptombusinessEndoscopy
researchProduct

A case of bowel schistosomiasis not adhering to endoscopic findings

2005

Schistosomiasis is a chronic worm infection caused by a species of trematodes, the Schistosomes. We may distinguish a urinary form from Schistosomes haematobium and an intestinal-hepatosplenic form mainly from Schistosomes mansoni characterized by nausea, meteorism, abdominal pain, bloody diarrhea, rectal tenesmus, and hepatosplenomegaly. These infections represent a major health issue in Africa, Asia, and South America, but recently S mansoni has increased its prevalence in other continents, such as Europe countries and North America, due to international travelers and immigrants, with several diagnostic and prevention problems. We report a case of a 24-year-old patient without HIV infecti…

AdultMaleAbdominal painmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatosplenomegalyColonoscopyCase ReportSchistosomiasisGastroenterologyPraziquantelFeceschemistry.chemical_compoundMesalazineIntestinal mucosaInternal medicineparasitic diseasesmedicineAnimalsHumansIntestinal MucosaParasite Egg CountSchistosomaAnthelminticsbiologymedicine.diagnostic_testGastroenterologybowel schistosomiasis; endoscopic findingsGeneral Medicinebiology.organism_classificationmedicine.diseaseRectal tenesmusSchistosomiasis mansonichemistryImmunologySchistosomamedicine.symptomWorld Journal of Gastroenterology
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct